Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 59263519100
Scopus Author ID: 57436191800

Activities

Collapse all

Employment (1)

Roche (Norway): Oslo, Oslo, NO

Employment
Source: Self-asserted source
Svenn Alexander Kommandantvold

Works (12)

A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom

Expert Review of Pharmacoeconomics & Outcomes Research
2024-09-13 | Journal article
DOI: 10.1080/14737167.2024.2365421
Contributors: Svenn Alexander Kommandantvold; Annabelle Lemenuel-Diot; Chris Skedgel; Richard Pitman; Peter Rouse; Hassan Zaraket; Hao Zhou; Marie-Helene Blanchet Zumofen
Source: check_circle
Crossref

Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States

Infectious Diseases and Therapy
2024-08-16 | Journal article
DOI: 10.1007/s40121-024-01027-9
Part of ISSN: 2193-8229
Part of ISSN: 2193-6382
Contributors: Svenn Alexander Kommandantvold; Shih-Chen Chang; Andy Surinach; Vincent Yau; Jennie H. Best; Hassan Zaraket; Hao Zhou; Jeff Frimpter; Marie-Helene Blanchet Zumofen
Source: Self-asserted source
Svenn Alexander Kommandantvold

Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies

Oncology and Therapy
2024-06 | Journal article
DOI: 10.1007/s40487-024-00264-9
Contributors: Svenn Alexander Kommandantvold; Nikos Kotsopoulos; Isabel Monteiro; Ana Ladeiras; Andrew Hogan; Felipe Barboza Magalhães de Araujo; Mark P. Connolly
Source: check_circle
Crossref

Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review

PharmacoEconomics
2023 | Journal article
DOI: 10.1007/s40273-022-01224-9
EID:

2-s2.0-85143897439

Part of ISSN: 11792027 11707690
Contributors: Zumofen, M.-H.B.; Frimpter, J.; Hansen, S.A.
Source: Self-asserted source
Svenn Alexander Kommandantvold via Scopus - Elsevier
grade
Preferred source (of 2)‎

Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States

Advances in Therapy
2023 | Journal article
DOI: 10.1007/s12325-023-02554-6
EID:

2-s2.0-85162871727

Part of ISSN: 18658652 0741238X
Contributors: Sussell, J.A.; Press, D.J.; Hansen, S.A.; Kim, E.; Du Toit, Y.; Fung, A.
Source: Self-asserted source
Svenn Alexander Kommandantvold via Scopus - Elsevier
grade
Preferred source (of 2)‎

The worldwide impact of HER2-targeted treatments in women with breast cancer: An epidemiological modeling study

2023 ASCO Annual Meeting
2023 | Conference poster | Validation, Formal analysis, Writing - original draft, Writing - review & editing, Methodology
Contributors: Svenn Alexander Kommandantvold
Source: Self-asserted source
Svenn Alexander Kommandantvold

Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.

Breast cancer (Tokyo, Japan)
2023-11-01 | Journal article
DOI: 10.1007/s12282-023-01514-w
PMID: 37907759
Contributors: Mellissa Yong Williamson; Press DJ; Hansen SA; Tomar A; Jhuti GS; Revil C; Gururaj K
Source: Self-asserted source
Svenn Alexander Kommandantvold
grade
Preferred source (of 2)‎

Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer

Advances in Therapy
2022 | Journal article
DOI: 10.1007/s12325-022-02047-y
EID:

2-s2.0-85123896872

Part of ISSN: 18658652 0741238X
Contributors: Sussell, J.A.; Roth, J.A.; Meyer, C.S.; Fung, A.; Hansen, S.A.
Source: Self-asserted source
Svenn Alexander Kommandantvold via Scopus - Elsevier

Correction to: Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer (Advances in Therapy, (2022), 39, 3, (1375-1392), 10.1007/s12325-022-02047-y)

Advances in Therapy
2022 | Journal article
DOI: 10.1007/s12325-022-02178-2
EID:

2-s2.0-85129479899

Part of ISSN: 18658652 0741238X
Contributors: Sussell, J.A.; Roth, J.A.; Meyer, C.S.; Fung, A.; Hansen, S.A.
Source: Self-asserted source
Svenn Alexander Kommandantvold via Scopus - Elsevier

A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction

European Journal of Health Economics
2020 | Journal article
DOI: 10.1007/s10198-019-01112-8
EID:

2-s2.0-85073965248

Part of ISSN: 16187601 16187598
Contributors: Hansen, S.A.; Aas, E.; Solli, O.
Source: Self-asserted source
Svenn Alexander Kommandantvold via Scopus - Elsevier

Low proportion of unreported cervical treatments in the cancer registry of Norway between 1998 and 2013

Acta Oncologica
2018 | Journal article
DOI: 10.1080/0284186X.2018.1497296
EID:

2-s2.0-85053276953

Part of ISSN: 1651226X 0284186X
Contributors: Leinonen, M.K.; Hansen, S.A.; Skare, G.B.; Skaaret, I.B.; Silva, M.; Johannesen, T.B.; Nygård, M.
Source: Self-asserted source
Svenn Alexander Kommandantvold via Scopus - Elsevier

A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction In the setting of recently introduced severity classifications and willingness-to-pay thresholds

DUO research Archive
2017 | Dissertation or Thesis
Contributors: Svenn Alexander Kommandantvold
Source: Self-asserted source
Svenn Alexander Kommandantvold
How many people are using ORCID?